Giant cell arteritis and therapeutic response: a dual facet of immunotherapy in metastatic clear cell renal carcinoma.

Autor:	Adjadé, Ganiou, Haag, Kelly, Meunier, Jérôme, Fadli, Mohammed El, Essadi, Ismail, Belbaraka, Rhizlane
Předmět:	IMMUNE checkpoint inhibitors NIVOLUMAB CANCER treatment IMMUNOTHERAPY CELL death GIANT cell arteritis RENAL cell carcinoma
Zdroj:	Oxford Medical Case Reports; Jul2024, Vol. 2024 Issue 7, p1-3, 3p
Abstrakt:	Immune checkpoint inhibitors have emerged as a promising cancer treatment, allowing significant and long-term therapeutic responses. Nivolumab, an anti-programmed cell death protein-1, is one of the molecules of this therapeutic class with known and manageable side effects. Giant cell arteritis is a rare immune-related adverse event most often manifested by headaches poorly released by common antalgics and can result in visual loss. We report its occurrence in an 80-year-old patient on maintenance nivolumab for metastatic clear cell renal carcinoma. Prompt diagnosis and initiation of glucocorticoid therapy led to symptom improvement and visual recovery. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.